Background :
In chemoradiotherapy (CRT) for treatment of esophageal cancer, complete response (CR) of the primary lesion could be a surrogate marker of good prognosis. We retrospectively analyzed the association between the response of primary lesion and the clinical outcomes of advanced esophageal cancer following the CRT.
Patients and Methods :
Twenty-eight patients underwent definitive CRT for advanced esophageal cancer between January 2009 and October 2010 at Kanagawa Cancer Center. Among these patients, 15 patients were further reviewed since they fulfilled the following criteria : 1) completion of the CRT course for squamous cell carcinoma of thoracic esophagus, 2) completion of the planned endoscopic examination, 3) confirmation of the disease progression or follow-up for more than 6 months after completing the treatment. Endoscopic evaluation of the primary lesion was performed at the two time points. One was after the CRT, while another was after the boost chemotherapy. According to the Guidelines for the Clinical and Pathological Studies on Carcinoma of the Esophagus (The 10th Edition) , the patients were categorized into primary-CR and non-CR groups. Statistics were performed by Kaplan-Meier method, Log-rank test, and Chi-square test. The data were analyzed in February 2011.
Result :
The characteristics of 17 patients were as follows : median age, 65 years ; male/female, 14/1 ; Stage (UICC) IIA/III/IVa/IVb, 1/11/1/2 Patients. After the first evaluation, only 4 exhibited CR at the primary site (primary CR) . Finally, 7 were diagnosed with primary CR after the boost chemotherapy. Median survival time was 414 days (range, 150-641 days) . Primary CR group showed good outcome in median survival and progression-free survival (442 days ; range,291-641, and 334 days ; range,231-604 days, respectively) compared with primary non-CR group (309 days ; range,150-490, and 175days ; range, 101-490 days, respectively) , with statistic significance (p=0.010 and 0.035, respectively) .
Discussion :
In our study, the primary-CR group tended to show better outcome than the non-CR group. The primary CR could be a surrogate marker for good prognosis in CRT for esophageal cancer, as previously reported. Primary-CR was confirmed after the boost chemotherapy in about half of the group. Close and careful endoscopic follow-up should be continued when the evaluation cannot be confirmed.
View full abstract